Susquehanna International Group
KTTAW

Susquehanna International Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Susquehanna International Group’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216 Buy
+24,293
New +$170 ﹤0.01% 13271
2025
Q4 		– Sell
-14,586
Closed -$247 – 13032
2025
Q3 		$247 Buy
+14,586
New +$242 ﹤0.01% 12225
2025
Q2 		– Sell
-10,579
Closed -$193 – 13243
2025
Q1 		$193 Buy
+10,579
New +$273 ﹤0.01% 12356
2022
Q4 		– Sell
-10,653
Closed -$2K – 13095
2022
Q3 		$2K Sell
10,653
-3,150
-23% -$311 ﹤0.01% 12951
2022
Q2 		$1K Buy
+13,803
New +$1.73K ﹤0.01% 12723

Other funds holding KTTAW

KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Susquehanna International Group's KTTAW Position: Q2 2026 in Review

Susquehanna International Group opened a new position in Pasithea Therapeutics Warrants (KTTAW) in Q2 2026: 24,293 shares worth $216. The stake represents ﹤0.01% of the portfolio and ranks #13271 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in KTTAW as recently as Q3 2025.

Susquehanna International Group first reported a position in KTTAW in Q2 2022 and has held it in 5 quarters since. The position peaked at $2K in Q3 2022. 6 funds tracked by Wall St. Rank hold KTTAW as of Q2 2026.

  • Susquehanna International Group held 24,293 shares of Pasithea Therapeutics Warrants worth $216 as of Q2 2026.
  • Pasithea Therapeutics Warrants was a new Susquehanna International Group position in Q2 2026.
  • Pasithea Therapeutics Warrants made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #13271 holding.
  • Susquehanna International Group first reported a position in Pasithea Therapeutics Warrants in Q2 2022 and has held it in 5 quarters since.
  • Susquehanna International Group's Pasithea Therapeutics Warrants position peaked at $2K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.